The patient, a veterinarian, had been self-administering oclacitinib (16–64 mg/day), a selective JAK1 inhibitor approved for the treatment of atopic dermatitis in dogs, daily for approximately 2 years to manage atopic dermatitis. Here, JAK1 is linked to atopic eczema.